SureTrader
Home > Boards > US OTC > Biotechs >

Inspyr Therapeutics Inc. (NSPX)

NSPX RSS Feed
Add NSPX Price Alert      Hide Sticky   Hide Intro
Moderator: Law of Averages
Search This Board: 
Last Post: 4/19/2018 10:56:53 AM - Followers: 50 - Board type: Free - Posts Today: 1





2511 N Loop 1604 W
Suite 204
San Antonio, TX 78258
Phone: 210-479-8112
Email: info@genspera.com

Website: http://www.genspera.com

Craig Dionne President, CEO, CFO
Russell Richerson COO, Secretary
 


Shares Outstanding 27,392,100 a/o Mar 09, 2014
Float Not Available
Authorized Shares 80,000,000 a/o Jun 30, 2009

Latest Report Mar 31, 2014 10-Q
CIK 0001421204
Fiscal Year End 12/31
 

About GenSpera

GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

Business Description

We are a biotechnology company focused on the discovery and development of pro-drug cancer therapeutics, an emerging medical science. A pro-drug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. We were incorporated as a Delaware corporation in 2003.

GenSpera Inc. (GenSpera) is a development-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors including prostate, liver, brain and other cancers. A prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. The Company has four prodrug candidates: G-202, G-114, G-115 and G-301. The Company's primary focus is the clinical development of its compound, G-202, a therapeutic agent with a mechanism of action. G-202 is in Phase II Clinical Trial. G-114 is validated efficacy in pre-clinical animal models. Pilot toxicology is completed for G-115. G-301 is validated efficacy in pre-clinical animal models. The Company is also conducting a Phase II clinical trial to test the utility of G-202 in patients with hepatocellular carcinoma (liver cancer). As of March 27, 2013, it treated one patient in this Phase II trial.


GenSpera harnesses a novel biomedical technology platform to deliver a powerful toxin directly to tumors

  • Phase II clinical trials for lead compound, G-202, are underway in two indications:
    • Hepatocellular carcinoma, or liver cancer
    • Glioblastoma, or brain cancer
  • Experienced and motivated team drives the process:
    • Core team has extensive experience in successfully identifying and bringing oncology treatments to the clinic.
    • Scientific Advisory Board is comprised of leading researchers who are both the inventors of the technology and shareholders.
  • Technology platform supports the development of a suite of drugs targeted at different cancers, as well as other applications such as imaging.
  • Over 15 years of research at Johns Hopkins Medical Center and other renowned research centers, including the University of Copenhagen.
    • Strong intellectual property portfolio
    • No milestones or royalty payments owed to third parties.
  • Leverage the team's passion and expertise in identifying promising treatments and bringing them to the clinic.




SureTrader
NSPX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
#875   Something smells foul with NSPX. waterchaser 04/12/18 11:09:41 PM
PostSubject
#920   Has anyone ever answered why they are not spread19 04/19/18 10:56:53 AM
#919   How does a heavily promoted stinky pinky drop waterchaser 04/18/18 07:29:02 PM
#918   Mipsagargin is the cancer grenade ! Mrragu 04/18/18 06:21:48 PM
#917   I'd say just consider yourself lucky to even wamuvoodoo 04/18/18 06:06:54 PM
#915   On the fence did my dd, can you spread19 04/18/18 11:07:08 AM
#914   NSPX heading south. waterchaser 04/18/18 10:44:05 AM
#913   Where’s the 10-K? Mrragu 04/18/18 09:56:26 AM
#912   Nice volume burst out the gate. Law of Averages 04/18/18 09:32:04 AM
#911   Good stuff, website? floridaboy 04/18/18 08:46:26 AM
#910   Thanks for sharing - always good DD. trustbutverifyit 04/18/18 07:45:38 AM
#909   $NSPX .02 heading to $1 and above CANCER TradingGems 04/17/18 11:57:06 PM
#908   $NSPX Uplisting to NASDAQ after merger with TradingGems 04/17/18 11:55:44 PM
#906   Not a good day for the NSPX promo. waterchaser 04/17/18 06:58:35 PM
#905   I'm seeing quite a few penny stocks putting Law of Averages 04/17/18 01:35:21 PM
#904   Dont think so.This is going to have a stocks2watch 04/17/18 12:16:31 PM
#903   Could see sub-penny this week. waterchaser 04/17/18 09:54:24 AM
#901   Definitely NOT a 'startup' or 'pump' as they tymerz 04/17/18 05:53:17 AM
#899   NSPX PUMP & DUMP CONFIRMED. waterchaser 04/16/18 06:03:26 PM
#898   I can't wait until we clear those .02s Law of Averages 04/16/18 05:19:23 PM
#897   Yes sir! Big Poppa Pump 04/16/18 05:06:05 PM
#896   NSPX looking like the big boys recognize the G-Schmoney 04/16/18 01:25:56 PM
#895   Nice! Let's go! G-Schmoney 04/16/18 01:24:41 PM
#894   $NSPX 3rd HIGHEST VOL IN ITS HISTORY @ TradingGems 04/16/18 12:00:01 PM
#893   Nice 490k bid at .0178 Law of Averages 04/16/18 11:02:48 AM
#892   just picked up 300+ thousand shares...let's make some cheese wamuvoodoo 04/16/18 10:59:57 AM
#891   That would be good..... someone knows it the TAKURI 04/16/18 10:57:20 AM
#890   From the looks of things. 016 seems to Law of Averages 04/16/18 10:53:36 AM
#889   NSPX looks like the PERFECT set up, trading G-Schmoney 04/16/18 10:46:38 AM
#888   GM! NSPX looking good this morning! G-Schmoney 04/16/18 10:44:29 AM
#887   NSPX action heating up! Volume coming G-Schmoney 04/16/18 10:43:50 AM
#886   GMA ! ?? TAKURI 04/16/18 07:07:43 AM
#885   The evidence of a NSPX promotion is easy waterchaser 04/15/18 06:00:18 PM
#884   $NSPX. I heard an analyst gave a $5 TradingGems 04/14/18 05:22:38 PM
#883   NSPX under "heavy" promotion???? Please tell us by TradingGems 04/14/18 05:10:33 PM
#882   As I thought, NSPX is under heavy promotion... waterchaser 04/13/18 08:32:48 PM
#881   NSPX recent merger, multiple collaborations with university hospitals, G-Schmoney 04/13/18 09:46:45 AM
#879   A RM merger into this looks possible. tymerz 04/13/18 05:55:33 AM
#875   Something smells foul with NSPX. waterchaser 04/12/18 11:09:41 PM
#874   NSPX only 9M O/S! Avg volume G-Schmoney 04/12/18 11:02:24 PM
#873   Buyer beware of the NSPX Pump and Dump. waterchaser 04/12/18 10:11:48 PM
#872   NSPX UNKNOWN. I've already posted STRAIGHT CONCENTRATED DD TradingGems 04/12/18 03:29:58 PM
#871   CDEL is not retail, retail lost everything with Dina 04/12/18 01:58:15 PM
#870   That's some great news to hear. Let's hope Law of Averages 04/12/18 01:57:48 PM
#869   A merger is possible, but they have issues Dina 04/12/18 01:52:51 PM
#868   I am doing a ton of DD right tymerz 04/12/18 01:49:02 PM
#867   We need a 10q bad. I'm curious to Law of Averages 04/12/18 01:44:40 PM
#866   Gotcha. Well it seems like Lewis and tymerz 04/12/18 01:35:18 PM
#865   Try to call Chris, his number is on Dina 04/12/18 01:31:22 PM
#864   You understood my post wrong. I never meant Dina 04/12/18 01:26:36 PM
#863   I call BS you called Robert Thompson. tymerz 04/12/18 01:21:13 PM
PostSubject